SNDX-5613 (Revumenib) Mechanism of Action: Menin Inhibition in Leukemic Cell Research

SNDX-5613 (Revumenib) MOA:Targeting Menin/HOX Pathway for Acute Leukemia

🎯 check SNDX-5613 (Revumenib) product page

SNDX-5613 is a menin inhibitor. It affects MLL/NPM1 signaling by enhancing CLL-1 expression, promoting CAR T cell immunity.

Primary Applications and Mechanism of Action